Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Laila Rahbar (NPI 1417140864)

Field	Value
Entity Type	Individual
Organization	Laila Rahbar
Address	329 Mclaws Cir
City	Williamsburg
State	VA
ZIP	23185
Taxonomy	Rheumatology Physician
NPI Enumerated	August 20, 2007

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This provider’s Medicare activity is heavily concentrated in infused and injectable biologic therapies: the top three revenue-driving codes are J0897 ($727.9K, 23.0%), J1745 ($603.6K, 19.0%), and J3245 ($473K, 14.9%), and these three codes together account for 56.9% of the provider’s Medicare revenue. The code mix (denosumab, infliximab, tildrakizumab and multiple other J‑codes) is consistent with a rheumatology practice that operates an on‑site infusion/administration service as a core revenue line rather than exclusively office E/M visits.

Revenue concentration is high: Medicare totals $3.2M in lifetime revenue while Medicaid billing is none, and the precomputed top‑3 share of 56.9% indicates a reliance on a small set of biologic infusion/drug codes for the majority of Medicare income. That concentration implies sensitivity to drug utilization, payer reimbursement changes for those specific J‑codes, or supply/contracting dynamics tied to these agents.

This provider is effectively single‑payer in scale: Medicare $3.2M versus Medicaid none on file, meaning any payer strategy or network negotiation should treat this relationship as heavily Medicare‑driven. Absence of Medicaid billing removes dual‑payer diversification and suggests contracting and utilization reviews should prioritize Medicare lines of business.

For specific biologics the provider is a national high‑volume outlier: J0897 ranks #42 of 10057 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code) and J1745 ranks #12 of 1352 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). These rank/label combinations indicate the provider is a major national outlier in administering denosumab and infliximab relative to peers, signaling market dominance for those specific agents.

Infusion and chemotherapy administration activity is substantial and also shows unusually high national standing for some administration codes: 96413 ($84.2K) ranks in the 98th percentile and is described as notably above typical national volume, 96401 ($52.7K) is in the 98th percentile and labeled an extreme outlier, and 96415 ($11.5K) is in the 99th percentile and labeled an extreme outlier. The elevated volumes for these administration/infusion add‑on codes plus high counts for 96372 ($9.4K, 99th percentile; extreme outlier) reinforce that the practice runs regular, high-throughput infusion sessions rather than only episodic injections.

While several J‑drugs dominate revenue, other biologics and related agents are present at notable levels: J3262 (tocilizumab) generated $446.6K (14.1%) and is ranked #72 of 618 providers nationally (88th percentile; typical, unremarkable volume), and J0129 (abatacept) contributed $266.1K (8.4%) with a mid‑range national rank (47th percentile; typical, unremarkable volume). This mix shows a broad portfolio of rheumatologic biologics beyond the top two drugs, with some codes at typical peer volumes and others at elevated volumes.

The practice maintains an outpatient clinical footprint in addition to infusion services: office E/M codes 99214 ($44.3K, 1.4%) and 99215 ($34.7K, 1.1%) generate modest shares of revenue, and DXA imaging 77080 produced $12.4K (0.4%). These smaller but consistent outpatient and diagnostic codes indicate ongoing longitudinal rheumatology care and bone‑health services supporting the infusion business.

Provider tenure and geography: the NPI was enumerated on 2007-08-20 (~19 years ago), indicating an established presence in WILLIAMSBURG, VA. Coupled with the national outlier status on selected biologic and infusion codes, this tenure suggests an entrenched local/regional infusion practice that draws sufficient volume to place it well above most peers on specific Medicare drug and administration measures.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

30 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	40,440	$20	$727.9K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	23,220	$30	$603.6K
J3245	Injection, tildrakizumab, 1 mg	4,300	$110	$473K
J3262	Injection, tocilizumab, 1 mg	89,320	$10	$446.6K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	7,830	$30	$266.1K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	60,400	$1	$241.6K
J1602	Injection, golimumab, 1 mg, for intravenous use	12,100	$10	$121K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	810	$100	$84.2K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	980	$50	$52.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	480	$90	$44.3K

Showing 1–10 of 30

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 30 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Laila Rahbar — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

30 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3245	5	10	4,700	$110	$728K
J0129	24	30	10,450	$30	$407.3K
J3262	4	20	75,870	$1	$383.3K
J0717	22	30	74,500	$1	$361.7K
J1745	3	30	4,540	$30	$200.2K
J1602	13	20	13,430	$10	$176.7K
J0897	2	340	2,820	$20	$89.3K
96413	7	230	250	$100	$28.5K
99214	2,056	12,890	140	$80	$21K
96401	5	180	110	$60	$11.5K

Showing 1–10 of 30

Related Providers

Other providers that share a Tax Identification Number (TIN) with Laila Rahbar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Elena Flagg	VA	Rheumatology Physician	$3.8M	$0
Misty White	VA	Family Nurse Practitioner	$1.2M	$0
Audra Albert	VA	Family Nurse Practitioner	$639.8K	$0
Danielle Nabers	VA	Physician Assistant	$99.6K	$0

Nearby Providers

Other providers in the same ZIP code as Laila Rahbar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Colonial Behavioral Health	VA	Community/Behavioral Health Agency	$0	$21.6M
Riverside Physician Services Inc	VA	Emergency Medicine Physician	$0	$17.3M
Michumi PLLC	VA	Emergency Medicine Physician	$0	$12.4M
Doctors' Hospital Of Williamsburg	VA	General Acute Care Hospital	$0	$12M
Connect Youth And Family Services	VA	Community/Behavioral Health Agency	$0	$6M
James City County Board Of Supervisors	VA	Ambulance	$1.2M	$822.4K
Zantha Marcuson	VA	MOHS-Micrographic Surgery Physician	$886K	$0
Anthony Farah	VA	Ophthalmology Physician	$653.9K	$0
Eric Karlin	VA	Allergy & Immunology Physician	$564.6K	$1.6K
Emily Himes	VA	Dermatology Physician	$463.4K	$0

Laila Rahbar — Billing Profile & Reimbursement Data

Sign up for Laila Rahbar — Billing Profile & Reimbursement Data policy alerts

Laila Rahbar — Billing Profile & Reimbursement Data

Sign up for Laila Rahbar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References